APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/APM.v11i4.1871ArticleThe Correlation and Diagnostic Value of Serum MBL, MASP1, MASP2, and Coagulation Function Indexes in Children with Acute Leukemia Complicated by Infectionhttps://artdesignp.com/journal/APM/11/4/10.18063/APM.v11i4.1871XiongSimin20261142026-04-26Objective: To explore the correlation and diagnostic value of serum mannose-binding lectin (MBL), mannose-binding lectin-associated serine protease 1 (MASP1), and MASP2 levels and coagulation function indexes in children with acute leukemia complicated by infection. Methods: A retrospective analysis was conducted on the clinical data of 149 pediatric patients with acute leukemia admitted to our hospital from January 1, 2023, to December 31, 2025. The patients were categorized into three groups based on their infection status: sepsis (38 cases), common infection (51 cases), and non-infection (60 cases). Serum levels of MBL, MASP1, and MASP2 were measured using ELISA. Coagulation function tests were performed to analyze D-dimer (D-D), prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen (FIB) levels. Pearson correlation analysis was used to explore the relationship between serum MBL, MASP1, MASP2, and coagulation function indicators. The diagnostic performance of each indicator, both individually and in combination, was evaluated using receiver operating characteristic (ROC) curves. Results: The serum levels of MBL (1889.18 ± 174.91 ng/mL), MASP1 (31.01 ± 3.60 ng/mL), MASP2 (555.81 ± 55.90 pg/mL), and coagulation function indicators (APTT, PT, FIB, D-D) in the sepsis group were significantly higher than those in the common infection group and the non-infection group (P < 0.05). Pearson correlation analysis showed a significant positive correlation between serum MBL, MASP1, MASP2, and coagulation function indicators (P < 0.05). ROC curve analysis showed that the AUC of MBL, MASP1, and MASP2 was 0.675, 0.782, and 0.745, respectively when detected alone, while the AUC of the three combined tests was 0.842, with a sensitivity of 86.0% and a specificity of 82.0%. The diagnostic performance was significantly better than that of the single test. Conclusion: The levels of serum MBL, MASP1, and MASP2, along with coagulation function indicators, were significantly elevated in children with acute leukemia complicated by infection. These three factors are closely related to coagulation function indicators. Jointly testing MBL, MASP1, and MASP2 provides a high diagnostic value for the condition, offering crucial evidence for early clinical diagnosis and disease assessment.Acute leukemia,MBL,MASP1,MASP2,Coagulation function

[1] Abdelaziz H, Abdellateif M, Elnaggar G, et al., 2025, The Decay-Accelerating Factor (CD55) in Acute Leukemia Patients and Its Query Implication in Cancer Pathogenesis, Journal of the Egyptian National Cancer Institute, 37(1): 42. [2] Petinati N, Sadovskaya A, Shipounova I, et al., 2025, Blood Serum from Patients with Acute Leukemia Inhibits the Growth of Bone Marrow Multipotent Mesenchymal Stromal Cells, Biomedicines, 13(5): 1265–1265. [3] Chen Z, 1999, The Third Pathway of Complement Activation: The Lectin Pathway, International Medical Journal: Molecular Biology Section, 21(5): 295. [4] Sahu SK, Kulkarni DH, Ozanturk AN, et al., 2022, Emerging Roles of the Complement System in Host-Pathogen Interactions, Trends Microbiol, 30(4): 390–402. [5] Brooks A, 2015, Distinct Contributions of Model MASP1 and MASP2 Like Peptides to the Mechanical Properties of Synthetic Major Ampullate Silk Fibers as Revealed In Silico, Nanotechnol, Appl, 1: 9–16. [6] Sudha V, Abhishek M, Yousuf AM, et al., 2018, Leishmania donovani Inhibitor of Serine Peptidases 2 Mediated Inhibition of Lectin Pathway and Upregulation of C5aR Signaling Promote Parasite Survival inside Host, Frontiers in Immunology, 9: 63. [7] Teillet F, Gaboriaud C, Lacroix M, et al., 2008, Crystal Structure of the CUB1-EGF-CUB2 Domain of Human MASP-1/3 and Identification of Its Interaction Sites with Mannan-Binding Lectin and Ficolins, Journal of Biological Chemistry, 283(37): 25715–25724. [8] Wang F, Chen Z, 2002, Glycanspecific Serine Proteases Associated with Lectins, Biochemistry, (2): 100–102. [9] Wallis R, Dodds AW, Mitchell DA, et al., 2007, Molecular Interactions between MASP-2, C4, and C2 and Their Activation Fragments Leading to Complement Activation via the Lectin Pathway, Journal of Biological Chemistry, 282(11): 7844–7851. [10] Degn SE, Jensenius JC, Thiel S, 2013, Mannan-Binding Lectin-Associated Serine Protease (MASP)-1 Is Crucial for Lectin Pathway Activation in Human Serum, whereas neither MASP-1 nor MASP-3 Is Required for Alternative Pathway Function, Journal of Immunology, 190(6): 2477–2478. [11] Asgari E, Farrar CA, Lynch N, et al., 2014, Mannan-Binding Lectin-Associated Serine Protease 2 Is Critical for the Development of Renal Ischemia Reperfusion Injury and Mediates Tissue Injury in the Absence of Complement C4, The FASEB Journal, 28(9): 3996–4003. [12] Ameye L, Paesmans M, Thiel S, et al., 2012, M-ficolin Levels Are Associated with the Occurrence of Severe Infections in Patients with Haematological Cancer Undergoing Chemotherapy, Clinical & Experimental Immunology, 167(2): 303–308. [13] Asgari E, Farrar CA, Lynch N, et al., 2014, Mannan-Binding Lectin-Associated Serine Protease 2 Is Critical for the Development of Renal Ischemia Reperfusion Injury and Mediates Tissue Injury in the Absence of Complement C4, The FASEB Journal, 28(9): 3996–4003. [14] Li L, Mo QH, Xu XM, 2005, Rapid, Accurate Genotyping of Alcohol Dehydrog-Enase-1B and Aldehyde Dehydrogenase-2 Based on the Use of Denaturing HPLC, Clin Chem Lab Med, 43: 1334–1338. [15] Zehnder A, Fisch U, Hirt A, et al., 2009, Prognosis in Pediatric Hematologic Malignancies is Associated with Serum Concentration of Mannose-Binding Lectin-Associated Serine Protease-2 (MASP-2), Pediatr Blood Cancer, 53: 53–57. [16] Ogasawara M, Miyashita M, Yamagishi Y, et al., 2025, Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms’ Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients, EJHaem, 6(3): e70048. [17] Soundararajan R, Yadav A, Avs KA, et al., 2025, A Case Report of Neuroleukemiosis Detected on FDG PET Scan in a Patient of Mixed Phenotype Acute Leukemia Post Bone Marrow Transplantation in Remission, World Journal of Nuclear Medicine, 24(2): 169–172. [18] Brown MA, Ross A, Belsky AJ, 2025, Vincristine-Induced Autonomic Neuropathy Diagnosed via Quantitative Sudomotor Axon Reflex Sweat Test in an Adolescent Patient With Acute Leukemia, Pediatric Blood & Cancer, e31783. [19] Wakasugi Y, Ikeda Y, Noda S, et al., 2025, Efficacy of 5-Hydroxytryptamine 3 Receptor Antagonists Versus Metoclopramide for Preventing Nausea and Vomiting During Azacitidine Chemotherapy in Patients with Myelodysplastic Syndromes or Acute Leukemia: A Retrospective Observational Study, Journal of Pharmaceutical Health Care and Sciences, 11(1): 36. [20] Zhao SX, Chen TX, Chang JY, 2025, Stem Cell Transplantation Indications for Patients with Acute Leukemia Determined by Measurable Residual Disease: What We Know and What We Do Not Know, Blood Science (Baltimore, Md.), 7(2): e00229. [21] Sherban A, Frisch A, Rozental A, et al., 2025, Epiglottitis in Patients Treated for Acute Leukemia - Case Series and Systematic Review of the Literature, Acta Haematologica, 21. [22] Yegin AZ, Yıldız Ş, Savaş ME, et al., 2025, Day +100 Bone Marrow Megakaryocyte Count Predicts Transplant Outcome in Patients with High-Risk Myelodysplastic Syndrome and Acute Leukemia, Journal of Hematopathology, 18(1): 18. [23] Karakus A, Toptas T, Dal SM, et al., 2025, Anti-T Lymphocyte Globulin Plus Posttransplant Cyclophosphamide 25 mg/kg Versus Posttransplant Cyclophosphamide 50 mg/kg in Patients with Acute Leukemias, Bone Marrow Transplantation, (prepublish): 1–9. [24] Zhang W, Cui Y, Wu J, et al., 2025, Incidence and Risk Factors of Venous Thromboembolism in Patients with Acute Leukemia: A Systematic Review and Meta-Analysis, Leukemia Research, 153107694. [25] Tarlovsky FV, Altamirano AK, Gutiérrez VF, 2025, Evaluation and Prognostic Impact of Nutrition in Patients with Acute Leukemia: A Narrative Review, Current Oncology Reports, 27(5): 1–9. [26] Esteve J, Nagler A, Labopin M, et al., 2025, Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT, American Journal of Hematology, 100(6): 954–962. [27] Nishant J, Megha S, Sumeet M, et al., 2023, Relevance of Vitamin D in Patients Undergoing HLA Matched Allogeneic Stem Cell Transplant for Acute Leukemia, Transplant Immunology, 81: 101925. [28] Imene H, Naila H, Bechir A, et al., 2023, Human Herpesvirus-8 Infection in Tunisian Adult Acute Leukemia Patients, African Health Sciences, 23(1): 504–510. [29] Pierre-Yves D, Sarah B, Caroline B, et al., 2022, Characteristics and Clinical Outcomes of SARS-CoV-2 Infection in Adult Patients with Acute Leukemia in France, Leukemia Research, 120: 106901. [30] V NK, A RS, Suchetha NK, et al., 2022, Correlation of Preferentially Expressed Antigen of Melanoma (PRAME) Gene Expression with Clinical Characteristics in Acute Leukemia Patients, Journal of Genetic Engineering and Biotechnology, 20(1): 97.